Skip to main content
. Author manuscript; available in PMC: 2022 Dec 1.
Published in final edited form as: Am J Ophthalmol. 2021 Jun 18;232:83–89. doi: 10.1016/j.ajo.2021.06.012

Table 1.

Demographic and glaucoma status data of subjects in the study sample. Mean values are reported with standard deviations (SD).

Characteristic Value (N=133 subjects)
Gender, n (%)
 Male 47 (35.3)
 Female 86 (64.7)
Age (yr), mean (SD) 60.9 (10.51)
Right Eye (N=133) Left Eye (N=132)
Number of glaucoma medications, n (%)
 0 8 (6.0) 7 (5.3)
 1 102 (76.7) 103 (78.0)
 2 19 (14.3) 18 (13.7)
 3 4 (4.0) 4 (3.0)
Glaucoma medication classes, n (%)
 Beta-blockers 79 (59.4) 79 (59.9)
 Prostaglandins 51 (38.4) 50 (37.9)
 Carbonic anhydrase inhibitors 9 (6.8) 9 (6.8)
 Adrenergic agonists 10 (7.5) 10 (7.6)
Central corneal thickness (μm), mean (SD) 535.9 (35.9) 537.5 (46.5)
Vertical cup-disc ratio, mean (SD) 0.63 (0.14) 0.63 (0.13)
Visual field mean deviation (dB), mean (SD) −4.18 (5.14) −4.07 (4.24)
Laser parameters, mean (SD)
 Total energy (milllijoules) 82.5 (18.8) 87.0 (18.5)
 Number of treatment spots 103.3 (3.5) 103.1 (3.1)